It remains unclear whether serum lipids influence colorectal cancer (CRC) risk.
We conducted a prospective cohort study of 380,087 adults aged 40–69 years in the UK Biobank. Serum high-density cholesterol, low-density cholesterol, total cholesterol, triglycerides, and apolipoprotein A and B were measured. We used Cox proportional hazard models to estimate the multivariable hazard ratios (HRs) of CRC according to one standard deviation (SD) increment in serum lipids. We conducted subgroup analysis by tumour anatomical subsites.
During a median of 10.3 years of follow-up, we documented 2667 incident CRC cases. None of the lipid biomarkers was associated with the risk of CRC after adjusting for potential confounding factors, including body mass index and waist circumference. When assessed by cancer subsites, serum triglycerides was associated with an increased risk of cancer in the caecum and transverse colon, with the HR of 1.12 (95% CI, 1.00–1.25) and 1.29 (95% CI, 1.09–1.53), respectively; and apolipoprotein A was associated with a lower risk of hepatic flexure cancer (HR, 0.73, 95% CI, 0.56–0.96).
Serum lipid profiles were not associated with colorectal cancer risk after adjusting for obesity indicators. The potential subsite-specific effects of triglycerides and apolipoprotein A require further confirmation.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Keum, N. & Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 16, 713–732 (2019).
Clinton, S. K., Giovannucci, E. L. & Hursting, S. D. The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: impact and future directions. J. Nutr. 150, 663–671 (2019).
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V. et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J. Clin. Lipido. 7, 304–383 (2013).
Pakiet, A., Kobiela, J., Stepnowski, P., Sledzinski, T. & Mika, A. Changes in lipids composition and metabolism in colorectal cancer: a review. Lipids Health Dis. 18, 29 (2019).
Bardou, M., Barkun, A. N. & Martel, M. Obesity and colorectal cancer. Gut 62, 933–947 (2013).
Johnson, C. M., Wei, C., Ensor, J. E., Smolenski, D. J., Amos, C. I., Levin, B. et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control 24, 1207–1222 (2013).
Long, J., Zhang, C.-J., Zhu, N., Du, K., Yin, Y.-F., Tan, X. et al. Lipid metabolism and carcinogenesis, cancer development. Am. J. Cancer Res. 8, 778–791 (2018).
Ackerman, D. & Simon, M. C. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol. 24, 472–478 (2014).
Hsu, I. R., Kim, S. P., Kabir, M. & Bergman, R. N. Metabolic syndrome, hyperinsulinemia, and cancer. Am. J. Clin. Nutr. 86, 867S–871S (2007).
Wang, C., Li, P., Xuan, J., Zhu, C., Liu, J., Shan, L. et al. Cholesterol enhances colorectal cancer progression via ROS elevation and MAPK signaling pathway activation. Cell. Physiol. Biochem. 42, 729–742 (2017).
Wang, Y., Liu, C. & Hu, L. Cholesterol regulates cell proliferation and apoptosis of colorectal cancer by modulating miR-33a-PIM3 pathway. Biochem. Biophys. Res. Commun. 511, 685–692 (2019).
Borgquist, S., Butt, T., Almgren, P., Shiffman, D., Stocks, T., Orho-Melander, M. et al. Apolipoproteins, lipids and risk of cancer. Int. J. Cancer 138, 2648–2656 (2016).
Coppola, J. A., Shrubsole, M. J., Cai, Q., Smalley, W. E., Dai, Q., Ness, R. M. et al. Plasma lipid levels and colorectal adenoma risk. Cancer Causes Control 26, 635–643 (2015).
Aleksandrova, K., Jenab, M., Bueno-de-Mesquita, H. B., Fedirko, V., Kaaks, R., Lukanova, A. et al. Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur. J. Epidemiol. 29, 261–275 (2014).
Yao, X. & Tian, Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control 26, 257–268 (2015).
Choi, Y. J., Lee, D. H., Han, K. D., Shin, C. M. & Kim, N. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. Eur. J. Epidemiol. 33, 1077–1085 (2018).
Li, M., Lu, J., Fu, J., Wan, Q., Wang, T., Huo, Y. et al. The association and joint effect of serum cholesterol, glycemic status with the risk of incident cancer among middle-aged and elderly population in china cardiometabolic disease and cancer cohort (4C)-study. Am. J. Cancer Res. 10, 975–986 (2020).
Tian, Y., Wang, K., Li, J., Wang, J., Wang, Z., Fan, Y. et al. The association between serum lipids and colorectal neoplasm: a systemic review and meta-analysis. Public Health Nutr. 18, 3355–3370 (2015).
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F. & Straif, K. Body fatness and cancer—viewpoint of the IARC Working Group. N. Engl. J. Med. 375, 794–798 (2016).
Petrelli, F., Tomasello, G., Borgonovo, K., Ghidini, M., Turati, L., Dallera, P. et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 3, 211–219 (2017).
Wang, L., Lo, C. H., He, X., Hang, D., Wang, M., Wu, K. et al. Risk factor profiles differ for cancers of different regions of the colorectum. Gastroenterology. https://doi.org/10.1053/j.gastro.2020.03.054 (2020).
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S. & Tabernero, J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79–92 (2017).
Burón Pust, A., Alison, R., Blanks, R., Pirie, K., Gaitskell, K., Barnes, I. et al. Heterogeneity of colorectal cancer risk by tumour characteristics: large prospective study of UK women. Int. J. Cancer 140, 1082–1090 (2017).
Laake, I., Thune, I., Selmer, R., Tretli, S., Slattery, M. L. & Veierød, M. B. A prospective study of body mass index, weight change, and risk of cancer in the proximal and distal colon. Cancer Epidemiol. Biomark. Prev. 19, 1511–1522 (2010).
Shin, A., Joo, J., Bak, J., Yang, H. R., Kim, J., Park, S. et al. Site-specific risk factors for colorectal cancer in a Korean population. PLoS ONE 6, e23196 (2011).
Agnoli, C., Grioni, S., Sieri, S., Sacerdote, C., Vineis, P., Tumino, R. et al. Colorectal cancer risk and dyslipidemia: a case–cohort study nested in an Italian multicentre cohort. Cancer Epidemiol. 38, 144–151 (2014).
Demb, J., Earles, A., Martínez, M. E., Bustamante, R., Bryant, A. K., Murphy, J. D. et al. Risk factors for colorectal cancer significantly vary by anatomic site. BMJ Open Gastroenterol. 6, e000313 (2019).
Murphy, N., Ward, H. A., Jenab, M., Rothwell, J. A., Boutron-Ruault, M. C., Carbonnel, F. et al. Heterogeneity of colorectal cancer risk factors by anatomical subsite in 10 European countries: a multinational cohort study. Clin. Gastroenterol. Hepatol. 17, 1323–1331.e1326 (2019).
Siegel, R. L., Miller, K. D. & Jemal, A. Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970–2014. Jama 318, 572–574 (2017).
Liu, P. H., Wu, K., Ng, K., Zauber, A. G., Nguyen, L. H., Song, M. et al. Association of obesity with risk of early-onset colorectal cancer among women. JAMA Oncol. 5, 37–44 (2019).
Collins, R. What makes UK Biobank special? Lancet 379, 1173–1174 (2012).
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
Rosner, B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 25, 165–172 (1983).
Elliott, P., Peakman, T. C. & Biobank, o. b. o. U. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37, 234–244 (2008).
Peakman, T. C. & Elliott, P. The UK Biobank sample handling and storage validation studies. Int. J. Epidemiol. 37, i2–i6 (2008).
Project, U. B. B. Companion Document to Accompany Serum Biomarker Data, https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf (2019).
Guo, W., Bradbury, K. E., Reeves, G. K. & Key, T. J. Physical activity in relation to body size and composition in women in UK Biobank. Ann. Epidemiol. 25, 406–413.e406 (2015).
Liu, B., Young, H., Crowe, F. L., Benson, V. S., Spencer, E. A., Key, T. J. et al. Development and evaluation of the Oxford WebQ, a low-cost, web-based method for assessment of previous 24 h dietary intakes in large-scale prospective studies. Public Health Nutr. 14, 1998–2005 (2011).
Hankinson, S. E., Manson, J. E., Spiegelman, D., Willett, W. C., Longcope, C. & Speizer, F. E. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol. Biomark. Prev. 4, 649–654 (1995).
Wang, M., Spiegelman, D., Kuchiba, A., Lochhead, P., Kim, S., Chan, A. T. et al. Statistical methods for studying disease subtype heterogeneity. Stat. Med. 35, 782–800 (2016).
Benjamin, D. J., Berger, J. O., Johannesson, M., Nosek, B. A., Wagenmakers, E. J., Berk, R. et al. Redefine statistical significance. Nat. Hum. Behav. 2, 6–10 (2018).
van Duijnhoven, F. J. B., Bueno-De-Mesquita, H. B., Calligaro, M., Jenab, M., Pischon, T., Jansen, E. H. J. M. et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 60, 1094–1102 (2011).
Wulaningsih, W., Garmo, H., Holmberg, L., Hammar, N., Jungner, I., Walldius, G. et al. Serum lipids and the risk of gastrointestinal malignancies in the Swedish AMORIS Study. J. Cancer Epidemiol. 2012, 792034 (2012).
Chapman, T. P., Gomes, C. F., Louis, E., Colombel, J.-F. & Satsangi, J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 5, 63–79 (2020).
Ibáñez-Sanz, G., Díez-Villanueva, A., Riera-Ponsati, M., Fernández-Villa, T., Fernández Navarro, P., Bustamante, M. et al. Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause. Sci. Rep. 9, 13407 (2019).
Dong, Y., Zhou, J., Zhu, Y., Luo, L., He, T., Hu, H. et al. Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies. Biosci. Rep. 37, BSR20170945 (2017).
Ma, Y., Yang, Y., Wang, F., Zhang, P., Shi, C., Zou, Y. et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS ONE 8, e53916 (2013).
Giovannucci, E., Ascherio, A., Rimm, E. B., Colditz, G. A., Stampfer, M. J. & Willett, W. C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann. Intern. Med. 122, 327–334 (1995).
Larsson, S. C. & Wolk, A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am. J. Clin. Nutr. 86, 556–565 (2007).
Dai, Z., Xu, Y. C. & Niu, L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J. Gastroenterol. 13, 4199–4206 (2007).
Soltani, G., Poursheikhani, A., Yassi, M., Hayatbakhsh, A., Kerachian, M. & Kerachian, M. A. Obesity, diabetes and the risk of colorectal adenoma and cancer. BMC Endocr. Disord. 19, 113 (2019).
Chun, K. A., Kocarnik, J. M., Hardikar, S. S., Robinson, J. R., Berndt, S. I., Chan, A. T. et al. Leptin gene variants and colorectal cancer risk: sex-specific associations. PLoS ONE 13, e0206519 (2018).
Song, M., Gong, J., Giovannucci, E. L., Berndt, S. I., Brenner, H., Chang-Claude, J. et al. Genetic variants of adiponectin and risk of colorectal cancer. Int. J. Cancer 137, 154–164 (2015).
Kern, L., Mittenbühler, M. J., Vesting, A. J., Ostermann, A. L., Wunderlich, C. M. & Wunderlich, F. T. Obesity-induced TNFα and IL-6 signaling: the missing link between obesity and inflammation-driven liver and colorectal cancers. Cancers (Basel) 11, 24 (2018).
Xu, J., Ye, Y., Wu, H., Duerksen-Hughes, P., Zhang, H., Li, P. et al. Association between markers of glucose metabolism and risk of colorectal cancer. BMJ Open 6, e011430 (2016).
Vekic, J., Zeljkovic, A., Stefanovic, A., Jelic-Ivanovic, Z. & Spasojevic-Kalimanovska, V. Obesity and dyslipidemia. Metabolism 92, 71–81 (2019).
Klop, B., Elte, J. W. & Cabezas, M. C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 5, 1218–1240 (2013).
Pagliassotti, M. J., Kim, P. Y., Estrada, A. L., Stewart, C. M. & Gentile, C. L. Endoplasmic reticulum stress in obesity and obesity-related disorders: an expanded view. Metabolism 65, 1238–1246 (2016).
Bufill, J. A. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann. Intern. Med. 113, 779–788 (1990).
Irrazábal, T., Belcheva, A., Girardin, S. E., Martin, A. & Philpott, D. J. The multifaceted role of the intestinal microbiota in colon cancer. Mol. Cell 54, 309–320 (2014).
James, K. R., Gomes, T., Elmentaite, R., Kumar, N., Gulliver, E. L., King, H. W. et al. Distinct microbial and immune niches of the human colon. Nat. Immunol. 21, 343–353 (2020).
Song, M., Chan, A. T. & Sun, J. Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology 158, 322–340 (2020).
O’keefe, S. J. Diet, microorganisms and their metabolites, and colon cancer. Nat. Rev. Gastroenterol. Hepatol. 13, 691 (2016).
Vieira-Silva, S., Falony, G., Belda, E., Nielsen, T., Aron-Wisnewsky, J., Chakaroun, R. et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 581, 310–315 (2020).
We thank the UK Biobank participants and individuals who built the open access resource.
Ethics approval and consent to participate
All participants have provided their informed consent to participate. Studies based on UK Biobank were performed in accordance with the Declaration of Helsinki. Ethical approval and consent were granted by the North West-Haydock NRES multicentre ethics committee, REF: 16NW/0274.
Approval for the study and permission to access the data was granted by the UK Biobank Resource under Application Number 46466 that is open access. Bona fide researchers can access the UK Biobank dataset by registering and applying at http://ukbiobank.ac.uk/register-apply/.
The authors declare no competing interests.
This work was supported by the American Cancer Society (MRSG-17-220-01-NEC to M.S.) and the U.S. National Institutes of Health (R00 CA215314 to M.S.). The UK Biobank was primarily funded by the Wellcome Trust and the Medical Research Council. Other areas of funding include the United Kingdom Department of Health, the Scottish Government, the Welsh Assembly Government, the British Heart Foundation, and Diabetes UK.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fang, Z., He, M. & Song, M. Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank. Br J Cancer 124, 663–670 (2021). https://doi.org/10.1038/s41416-020-01143-6